Core Viewpoint - Nocera Biopharma (09969) shares rose over 3%, currently up 3.5% at HKD 18.63, with a trading volume of HKD 133 million, ahead of the board meeting scheduled for August 19 to approve mid-term results [1] Group 1: Financial Performance - Nocera Biopharma's first-quarter revenue increased by 130% year-on-year, with net profit turning positive at HKD 1.8 billion, exceeding expectations due to strong growth of its core product, Oubreti, and confirmation of upfront payment from Prolium [1] - CICC has revised its profit forecasts for Nocera Biopharma, narrowing expected losses for the next two years from HKD 436 million and HKD 256 million to HKD 415 million and HKD 225 million, respectively [1] Group 2: Product Insights - Oubreti, a BTK inhibitor developed by Nocera Biopharma, is primarily used for treating chronic lymphocytic leukemia and is gaining market share, holding a significant position in the domestic BTK inhibitor market [1] - In 2024, Oubreti's sales revenue is projected to exceed HKD 1 billion, representing a year-on-year growth of 49.14%, capturing a 30% market share in the domestic BTK inhibitor market [1]

Core Viewpoint - Nocera Health (09969) has seen a stock increase of over 3%, currently at 18.63 HKD, with a trading volume of 133 million HKD, ahead of its board meeting scheduled for August 19 to approve mid-term results [1] Financial Performance - Nocera Health's first-quarter revenue increased by 130% year-on-year, with net profit turning positive at 1.8 billion HKD, exceeding expectations due to strong growth of its core product, Oubreti [1] - CICC has revised its profit forecasts for Nocera Health, narrowing expected losses for the next two years from 436 million HKD and 256 million HKD to 415 million HKD and 225 million HKD respectively [1] Product Insights - Oubreti, a BTK inhibitor developed by Nocera Health, is primarily used for treating chronic lymphocytic leukemia and has been gaining market share, holding a significant position in the domestic BTK inhibitor market [1] - In 2024, Oubreti's sales revenue is projected to exceed 1 billion HKD, representing a year-on-year growth of 49.14%, capturing a 30% market share in the domestic BTK inhibitor market [1]

Group 1 - The core viewpoint of the article highlights the positive impact of rising expectations for interest rate cuts in the US on the biotechnology sector, leading to a significant increase in the S&P Biotechnology Index by 2.89% [1] - The Hong Kong pharmaceutical sector continues to show strong performance, with the Hong Kong Pharmaceutical ETF (159718.SZ) rising by 0.38% [1] - Notable individual stock performances include a 6.22% increase for Simcere Pharmaceutical Group (02410), a 3.34% rise for BeiGene (06160), and a 2.29% increase for Kelun-Biotech (06990) [1] Group 2 - The liquidity in the market is robust, with the Hong Kong Pharmaceutical ETF seeing a turnover of 13.3% and a transaction volume of 36.42 million yuan within the first 20 minutes of trading [1] - Guotai Junan Securities has stated that China's innovative drugs are on the rise, entering the initial phase of realizing innovation results, with significant opportunities for independent development and large transactions through business development (BD) licensing [1] - The Hong Kong Pharmaceutical ETF focuses on 18 A-share biotechnology companies, including key innovative drug firms such as BeiGene, WuXi Biologics, and CSPC Pharmaceutical Group, benefiting from global innovation drug research dividends [1] Group 3 - The article emphasizes the favorable conditions for the innovative drug growth sector due to the anticipated US interest rate cuts, which are expected to benefit the domestic innovative drug companies as they expand internationally [1] - The recommendation is to pay attention to the Hong Kong Pharmaceutical ETF (159718.SZ) and its associated funds (Class A: 019598, Class C: 019599) as they are positioned to capitalize on these trends [1]

Investment Rating - The industry investment rating is "Outperform the Market" [1][47]. Core Insights - The white spot market for vitiligo treatment is vast, with a potential market size expected to reach 21.7 billion yuan by 2030, driven by an increasing number of patients and the need for effective treatments [3][15][39]. - Current treatment options are inadequate, with no approved products specifically for vitiligo in China, highlighting a significant gap in the market that innovative drugs could fill [3][26]. - The competitive landscape is favorable, with several small pharmaceutical companies and leading firms vying for market share, and key products expected to receive approval soon [3][39]. Summary by Sections Part 1: Patient Demographics and Health Risks - The prevalence of vitiligo is significant, with approximately 22.83 million patients in China, of which 54.01% are receiving treatment [3][15]. - The condition is associated with severe psychological impacts, including a higher incidence of depression among patients [3][10]. Part 2: Current Treatment Limitations - Existing treatments, primarily involving drug therapy and phototherapy, have shown limited effectiveness, necessitating the introduction of new drugs with higher repigmentation rates [3][24]. - The current market lacks approved medications specifically for vitiligo, with existing drugs primarily approved for other conditions [3][26]. Part 3: Competitive Landscape and Drug Development - The vitiligo treatment sector is characterized by a lack of approved products, with several drugs in various stages of clinical trials, including one in Phase III and six in Phase II [3][39]. - JAK inhibitors are identified as key targets in drug development, with the first approved topical JAK1/JAK2 inhibitor, Ruxolitinib cream, showing promising sales growth [3][32][39]. - The innovative drug market for vitiligo is projected to reach 10 billion yuan, with significant interest in companies like Kangzheng Pharmaceutical and TianKang [3][39]. Part 4: Investment Recommendations - The report suggests focusing on the progress of drug development in the vitiligo sector and monitoring companies involved, including Kangzheng Pharmaceutical, TianKang, Huadong Medicine, and others [3][39].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

Core Viewpoint - The company, Innocare Pharma, will hold a half-year performance briefing on August 20, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3]. Group 1: Event Details - The performance briefing is scheduled for August 20, 2025, from 11:00 AM to 12:00 PM [5][6]. - The event will take place at the Shanghai Stock Exchange's online roadshow center [5][6]. - Investors can participate in the briefing through the internet by accessing the Shanghai Stock Exchange roadshow center [4][5]. Group 2: Investor Engagement - Investors can submit questions for the briefing from August 13 to August 19, 2025, via the roadshow center's "Pre-Question Collection" section or through the company's email [2][7]. - The company will address commonly asked questions during the briefing [3][7]. - Contact information for the company's domestic securities affairs department is provided for further inquiries [7].

A 股代码：688428 A 股简称：诺诚健华 公告编号：2025-027 港股代码：09969 港股简称：诺诚健华 诺诚健华医药有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一） 会议召开时间：2025 年 8 月 20 日上午 11:00-12:00 重要内容提示： ? 会议召开时间：2025 年 8 月 20 日(星期三)上午 11:00-12:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 2025 年 8 月 13 日(星期三)至 8 月 19 日(星期二)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答 诺诚健华医药有限公司（以下简称"公司"）将于 2025 年 8 月 20 日发布公 司 2025 ...

（文章来源：证券日报） 证券日报网讯 8月11日晚间，诺诚健华发布公告称，公司将于2025年8月20日举行2025年半年度业绩说 明会。 ...

Group 1 - The stock price of Nuo Cheng Jian Hua-U is reported at 28.57 yuan, down 0.03% from the previous trading day, with a trading volume of 53,193 hands and a transaction amount of 1.52 billion yuan [1] - Nuo Cheng Jian Hua-U operates in the biopharmaceutical sector, focusing on the research and development of innovative drugs for oncology and autoimmune diseases. The company has achieved dual listing in A+H shares [1] - In Q1 2025, the total revenue increased by 129.9% year-on-year to 380 million yuan, with a profit of 14 million yuan for the quarter [1] Group 2 - Recent policies in the innovative drug industry have emerged, with the National Medical Products Administration approving 43 innovative drugs in the first half of the year, 40 of which were developed by Chinese companies [1] - The National Healthcare Security Administration has established a dynamic adjustment mechanism to expedite the inclusion of innovative drugs into medical insurance, while the drug administration has introduced a "30-day fast approval channel" to optimize the clinical trial review process [1] - On August 11, the net inflow of main funds was 3.5758 million yuan, accounting for 0.05% of the circulating market value, while over the past five days, the net outflow of main funds was 42.7503 million yuan, accounting for 0.56% of the circulating market value [1]

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《關於召開2025年半年度業績說明 會的公告》。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，二零二五年八月十一日 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 | | | 诺诚健华医药有限公司 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关 ...